192 related articles for article (PubMed ID: 37223910)
1. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.
Letson CT; Balasis ME; Newman H; Binder M; Vedder A; Kinose F; Ball M; Kruer T; Quintana A; Lasho TL; Finke CM; Almada LL; Grants JM; Zhang G; Fernandez-Zapico ME; Gaspar-Maia A; Lancet J; Komrokji R; Haura E; Sallman DA; Reuther GW; Karsan A; Rix U; Patnaik MM; Padron E
Clin Cancer Res; 2023 Aug; 29(15):2919-2932. PubMed ID: 37223910
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
4. The proto-oncogene Pim-1 is a target of miR-33a.
Thomas M; Lange-Grünweller K; Weirauch U; Gutsch D; Aigner A; Grünweller A; Hartmann RK
Oncogene; 2012 Feb; 31(7):918-28. PubMed ID: 21743487
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Liang C; Yu XJ; Guo XZ; Sun MH; Wang Z; Song Y; Ni QX; Li HY; Mukaida N; Li YY
Oncotarget; 2015 Jun; 6(16):14440-55. PubMed ID: 25971209
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
7. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
Chen NC; Borthakur G; Pemmaraju N
Leuk Lymphoma; 2021 Mar; 62(3):528-537. PubMed ID: 33161793
[TBL] [Abstract][Full Text] [Related]
9. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
11. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
[TBL] [Abstract][Full Text] [Related]
12. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Padron E; Painter JS; Kunigal S; Mailloux AW; McGraw K; McDaniel JM; Kim E; Bebbington C; Baer M; Yarranton G; Lancet J; Komrokji RS; Abdel-Wahab O; List AF; Epling-Burnette PK
Blood; 2013 Jun; 121(25):5068-77. PubMed ID: 23632888
[TBL] [Abstract][Full Text] [Related]
13. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
14. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens.
Wright S; Hu J; Wang H; Hyle J; Zhang Y; Du G; Konopleva MY; Kornblau SM; Djekidel MN; Rosikiewicz W; Xu B; Lu R; Yang JJ; Li C
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2220134120. PubMed ID: 37036970
[TBL] [Abstract][Full Text] [Related]
15. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
16. Targeting radioresistance and replication fork stability in prostate cancer.
Li X; Baek G; Carreira S; Yuan W; Ma S; Hofstad M; Lee S; Gao Y; Bertan C; Fenor de la Maza MLD; Alluri PG; Burma S; Chen BP; Raj GV; de Bono J; Pommier Y; Mani RS
JCI Insight; 2022 May; 7(9):. PubMed ID: 35349486
[TBL] [Abstract][Full Text] [Related]
17. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
[TBL] [Abstract][Full Text] [Related]
18. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
19. Targeting CCR2
Wu Y; Jennings NB; Sun Y; Dasari SK; Bayraktar E; Corvigno S; Stur E; Glassman D; Mangala LS; Lankenau Ahumada A; Westin SN; Sood AK; Hu W
J Cancer Res Clin Oncol; 2022 Apr; 148(4):803-821. PubMed ID: 35094142
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative potential of miR-33a in laryngeal cancer Hep-2 cells via targeting PIM1.
Karatas OF
Head Neck; 2018 Nov; 40(11):2455-2461. PubMed ID: 30102806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
